1 Ocak 2011 Dergi makalesi Açık Erişim

Alicikus, Zumre A.; Yamada, Yoshiya; Zhang, Zhigang; Pei, Xin; Hunt, Margie; Kollmeier, Marisa; Cox, Brett; Zelefsky, Michael J.

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 21197, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@type": "Person", 
      "affiliation": "Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA", 
      "name": "Alicikus, Zumre A."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA", 
      "name": "Yamada, Yoshiya"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA", 
      "name": "Zhang, Zhigang"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA", 
      "name": "Pei, Xin"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA", 
      "name": "Hunt, Margie"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA", 
      "name": "Kollmeier, Marisa"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA", 
      "name": "Cox, Brett"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA", 
      "name": "Zelefsky, Michael J."
    }
  ], 
  "datePublished": "2011-01-01", 
  "description": "BACKGROUND. The authors investigated long-term tumor control and toxicity outcomes after high-dose, intensity-modulated radiation therapy (IMRT) in patients who had clinically localized prostate cancer. METHODS. Between April 1996 and January 1998, 170 patients received 81 gray (Gy) using a 5-field IMRT technique. Patients were classified according to the National Comprehensive Cancer Network-defined risk groups. Toxicity data were scored according to the Common Terminology Criteria for Adverse Events Version 3.0. Freedom from biochemical relapse, distant metastases, and cause-specific survival outcomes were calculated. The median follow-up was 99 months. RESULTS. The 10-year actuarial prostate-specific antigen relapse-free survival rates were 81% for the low-risk group, 78% for the intermediate-risk group, and 62% for the high-risk group; the 10-year distant metastases-free rates were 100%, 94%, and 90%, respectively; and the 10-year cause-specific mortality rates were 0%, 3%, and 14%, respectively. The 10-year likelihood of developing grade 2 and 3 late genitourinary toxicity was 11% and 5%, respectively; and the 10-year likelihood of developing grade 2 and 3 late gastrointestinal toxicity was 2% and 1%, respectively. No grade 4 toxicities were observed. CONCLUSIONS. To the authors' knowledge, this report represents the longest followed cohort of patients who received high-dose radiation levels of 81 Gy using IMRT for localized prostate cancer. The findings indicated that high-dose IMRT is well tolerated and is associated with excellent long-term tumor-control outcomes in patients with localized prostate cancer Cancer 2011; 117: 1429-37. (C) 2010 American Cancer Society.", 
  "headline": "Ten-Year Outcomes of High-Dose, Intensity-Modulated Radiotherapy for Localized Prostate Cancer", 
  "identifier": 21197, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "license": "http://www.opendefinition.org/licenses/cc-by", 
  "name": "Ten-Year Outcomes of High-Dose, Intensity-Modulated Radiotherapy for Localized Prostate Cancer", 
  "url": "https://aperta.ulakbim.gov.tr/record/21197"
}